An Investigation into the Effects of Outer Membrane Vesicles and Lipopolysaccharide of Porphyromonas gingivalis on Blood-Brain Barrier Integrity,Permeability,and Disruption of Scaffolding Proteins in a Human in vitro Model
Restricted accessResearch articleFirst published online March 8, 2022
An Investigation into the Effects of Outer Membrane Vesicles and Lipopolysaccharide of Porphyromonas gingivalis on Blood-Brain Barrier Integrity,Permeability,and Disruption of Scaffolding Proteins in a Human in vitro Model
The effects of the key pathogens and virulence factors associated with gum disease such as Porphyromonas gingivalis (P. gingivalis) on the central nervous system is of great interest with respect to development of neuropathologies and hence therapeutics and preventative strategies. Chronic infections and associated inflammation are known to weaken the first line of defense for the brain, the blood-brain barrier (BBB).
Objective:
The focus of this study is to utilize an established human in vitro BBB model to evaluate the effects of P. gingivalis virulence factors lipopolysaccharide (LPS) and outer membrane vesicles (OMVs) on a primary-derived human model representing the neurovascular unit of the BBB.
Methods:
Changes to the integrity of the BBB after application of P. gingivalis LPS and OMVs were investigated and correlated with transport of LPS. Additionally, the effect of P. gingivalis LPS and OMVs on human brain microvascular endothelial cells in monolayer was evaluated using immunofluorescence microscopy.
Results:
The integrity of the BBB model was weakened by application of P. gingivalis LPS and OMVs, as measured by a decrease in electrical resistance and a recovery deficit was seen in comparison to the controls. Application of P. gingivalis OMVs to a monoculture of human brain microvascular endothelial cells showed disruption of the tight junction zona occludens protein (ZO-1) compared to controls.
Conclusion:
These findings show that the integrity of tight junctions of the human BBB could be weakened by association with P. gingivalis virulence factors LPS and OMVs containing proteolytic enzymes (gingipains).
AlonsoR, PisaD, MarinaAI, MoratoE, RábanoA, CarrascoL (2014) Fungal infection in patients with Alzheimer’s disease. J Alzheimers Dis41, 301–311.
2.
MiklossyJ (2016) Bacterial amyloid and DNA are important constituents of senile plaques: Further evidence of the spital and biofilm nature of senile plaques. J Alzheimers Dis53, 1459–1473roche.
3.
ItzhakiRF, LinWR, ShangD, WilcockGK, FaragherB, JamiesonGA (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet25, 241–244.
4.
PritchardAB, CreanS, OlsenI, SinghraoSK (2017) Periodontitis, microbiomes and their role in Alzheimer’s disease. Front Aging Neurosci24, 336.
5.
BraakH, BraakE (1990) [Morphology of Alzheimer disease]. Fortschr Med20, 621–624.
6.
FulopT, TripathiS, RodriguesS, DesrochesM, BuntT, EiserA, BernierF, BeauregardPB, BarronAE, KhalilA, PlotkaA, HirokawaK, LarbiA, BoctiC, LaurentB, FrostEH, WitkowskiJM (2021) Targeting impaired antimicrobial immunity in the brain for the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat4, 1311–1339.
7.
GuoT, ZhangD, ZengY, HuangTY, XuH, ZhaoY (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener15, 40.
8.
SevenichL (2018) Brain-resident microglia and blood-borne macrophages orchestrate central nervous system inflammation in neurodegenerative disorders and brain cancer. Front Immunol9, 697.
9.
SosciaSJ, KirbyJE, WashicoskyKJ, TuckerSM, IngelssonM, HymanB, BurtonMA, GoldsteinLE, DuongS, TanziRE, MoirRD (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One5, 9505.
10.
KumarDK, ChoiSH, WashicoskyKJ, EimerWA, TuckerS, GhofraniJ, LefkowitzA, McCollG, GoldsteinLE, TanziRE, MoirRD (2016) Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med8, 340ra72.
11.
VojdaniA, VojdaniE, SaidaraE, KharrazianD (2018) Reaction of Amyloid-β peptide antibody with different infectious agents involved in Alzheimer’s disease. J Alzheimers Dis63, 847–860.
12.
NaraPL, SindelarD, PennMS, PotempaJ, GriffinWST (2021) Porphyromonas gingivalis outer membrane vesicles as the major driver of and explanation for neuropathogenesis, the cholinergic hypothesis, iron dyshomeostasis, and salivary lactoferrin in Alzheimer’s disease. J Alzheimers Dis82, 1417–1450.
HajishengallisG, LamontRJ (2012) Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol27, 409–419.
15.
OlsenI, KellDB, PretoriusE (2020) Is Porphyromonas gingivalis involved in Parkinson’s disease?Eur J Clin Microbiol Infect Dis39, 2013–2018.
16.
HolmstrupP, DamgaardC, OlsenI, KlingeB, FlyvbjergA, NielsenCH, HansenPR (2017) Comorbidity of periodontal disease: Two sides of the same coin? An introduction for the clinician. J Oral Microbiol9, 1332710.
17.
KozakM, Dabrowska-ZamojcinE, Mazurek-MocholM, PawlikA (2020) Cytokines and their genetic polymorphisms related to periodontal disease. J Clin Med9, 4045.
18.
FornerL, LarsenT, KilianM, HolmstrupP (2006) Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol33, 401–407.
PooleS, SinghraoSK, KesavaluL, CurtisMA, CreanS (2013) Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer’s disease brain tissue. J Alzheimers Dis36, 665–677.
21.
VojdaniA, VojdaniE, HerbertM, KharrazianD (2020) Correlation between antibodies to bacterial lipopolysaccharides and barrier proteins in sera positive for ASCA and ANCA. Int J Mol Sci21, 1381.
22.
PooleS, SinghraoSK, ChukkapalliS, RiveraM, VelskoI, KesavaluL, CreanSJ (2015) Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/- mice brains. J Alzheimers Dis43, 67–80.
23.
IlievskiV, ZuchowskaPK, GreenSJ, TothPT, RagozzinoME, LeK, AljewariHW, O’Brien-SimpsonNM, ReynoldsEC, WatanabeK (2018) Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One13, e0204941.
24.
DornBR, BurksJN, SeifertKN, Progulske-FoxA (2000) Invasion of endothelial and epithelial cells by strains of Porphyromonas gingivalis. FEMS Microbiol Lett187, 139–144.
25.
YoshinoT, LaineML, Van WinkelhoffAJ, DahlénG (2007) Genotype variation and capsular serotypes of Porphyromonas gingivalis from chronic periodontitis and periodontal abscesses. FEMS Microbiol Lett270, 75–81.
26.
HaJY, ChoiSY, LeeJH, HongSH, LeeHJ (2020) Delivery of periodontopathogenic extracellular vesicles to brain monocytes and Microglial IL-6 promotion by RNA cargo. Front Mol Biosci7, 596366.
27.
VeithPD, ChenYY, GorasiaDG, ChenD, GlewMD, O’Brien-SimpsonNM, CecilJD, HoldenJA, ReynoldsEC (2014) Porphyromonas gingivalis outer membrane vesicles exclusively contain outer membrane and periplasmic proteins and carry a cargo enriched with virulence factors. J Proteome Res13, 2420–2432.
28.
AbeN, KadowakiT, OkamotoK, NakayamaK, OhishiM, YamamotoK (1998) Biochemical and functional properties of lysine-specific cysteine proteinase (Lys-gingipain) as a virulence factor of Porphyromonas gingivalis in periodontal disease. J Biochem123, 305–312.
29.
OlsenI, AmanoA (2015) Outer membrane vesicles - offensive weapons or good samaritans?J Oral Microbiol7, 27468.
MeghilMM, TawfikOK, ElashiryM, RajendranM, ArceRM, FultonDJ, SchoenleinPV, CutlerCW (2019) Disruption of immune homeostasis in human dendritic cells via regulation of autophagy and apoptosis by Porphyromonas gingivalis. Front Immunol10, 2286.
33.
DeatherageBL, CooksonBT (2012) Membrane vesicle release in bacteria, eukaryotes, and archaea: A conserved yet underappreciated aspect of microbial life. Infect Immun80, 1948–1957.
34.
NativelB, CouretD, GiraudP, MeilhacO, d’HellencourtCL, ViranaïckenW, Da SilvaCR (2017) Porphyromonas gingivalis lipopolysaccharides act exclusively through TLR4 with a resilience between mouse and human. Sci Rep7, 15789.
35.
MuoioV, PerssonPB, SendeskiMM (2014) The neurovascular unit - concept review. Acta Physiol (Oxf)210, 790–798.
36.
CipollaMJ (2009) The Cerebral Circulation. Morgan & Claypool Life Sciences, San Rafael, CA. Chapter 2, Anatomy and Ultrastructure. Available from: https://www.ncbi.nlm.nih.gov/books/NBK53086.
37.
SweeneyMD, SagareAP, ZlokovicBV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol14, 133–150.
38.
WolffA, AntfolkM, BrodinB, TenjeM (2015) In vitro blood–brain barrier models— an overview of established models and new microfluidic approaches. J Pharm Sci104, 2727–2746.
39.
VerheggenICM, de JongJJA, van BoxtelMPJ, GronenschildEHBM, PalmWM, PostmaAA, JansenJFA, VerheyFRJ, BackesWH (2020) Increase in blood–brain barrier leakage in healthy, older adults. Geroscience42, 1183–1193.
40.
LochheadJJ, YangJ, RonaldsonPT, DavisTP (2020) Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders. Front Physiology11, 914.
41.
BrownGC (2019) The endotoxin hypothesis of neurodegeneration. J Neuroinflammation16, 180.
42.
MethiaN, AndréP, Hafezi-MoghadamA, EconomopoulosM, ThomasKL, WagnerDD (2001) ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med7, 810–815.
DandoSJ, Mackay-SimA, NortonR, CurrieBJ, St JohnJA, EkbergJA, BatzloffM, UlettGC, BeachamIR (2014) Pathogens penetrating the central nervous system: Infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev27, 691–726.
45.
CoureuilM, LécuyerH, BourdoulousS, NassifX (2017) A journey into the brain: Insight into how bacterial pathogens cross blood-brain barriers. Nat Rev Microbiol15, 149–159.
46.
TakeuchiH, SasakiN, YamagaS, KuboniwaM, MatsusakiM, AmanoA (2019) Porphyromonas gingivalis induces penetration of lipopolysaccharide and peptidoglycan through the gingival epithelium via degradation of junctional adhesion molecule 1. PLoS Pathog15, e1008124.
47.
SheetsSM, PotempaJ, TravisJ, CasianoCA, FletcherHM (2005) Gingipains from Porphyromonas gingivalis W83 induce cell adhesion molecule cleavage and apoptosis in endothelial cells. Infect Immun73, 1543–1552.
48.
HeY, ShiotsuN, Uchida-FukuharaY, GuoJ, WengY, IkegameM, WangZ, OnoK, KamiokaH, ToriiY, SasakiA, YoshidaK, OkamuraH (2020) Outer membrane vesicles derived from Porphyromonas gingivalis induced cell death with disruption of tight junctions in human lung epithelial cells. Arch Oral Biol118, 104841.
49.
Solleiro-VillavicencioH, Rivas-ArancibiaS (2018) Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T cells in neurodegenerative diseases. Front Cell Neurosci12, 114.
50.
BanksWA, GrayAM, EricksonMA, SalamehTS, DamodarasamyM, SheibaniN, MeabonJS, WingEE, MorofujiY, CookDG, ReedMJ (2015) Lipopolysaccharide-induced blood-brain barrier disruption: Roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. J Neuroinflammation12, 223.
51.
WangX, XueGX, LiuWC, ShuH, WangM, SunY, LiuX, SunYE, LiuCF, LiuJ, LiuW Jin X (2017) Melatonin alleviates lipopolysaccharide-compromised integrity of blood–brain barrier through activating AMP-activated protein kinase in old mice. Aging Cell16, 414–421.
52.
PflanznerT, KuhlmannCR, PietrzikCU (2010) Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer’s disease. Curr Alzheimer Res7, 578–590.
53.
KumarS, ShawL, LawrenceC, LeaR, AlderJ (2014) Developing a physiologically relevant blood brain barrier model for the study of drug disposition in glioma’. Neurooncology16(Suppl 6), vi8.
54.
HughesP, MarshallD, ReidY, ParkesH, GelberC (2007) The costs of using unauthenticated, over-passaged cell lines: How much more data do we need?Biotechniques43, 577–578.
55.
SrinivasanB, KolliAR, EschMB, AbaciHE, ShulerML, HickmanJJ (2015) TEER measurement techniques for in vitro barrier model systems. J Lab Autom20, 107–126.
56.
ZwainTA, AlderJE, SabaghB, ShawA, BurrowAJ, SinghK (2021) Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through3D BBB/BBTB models. Mater Sci Eng C Mater Biol Appl121, 111774.
57.
SeyamaM, YoshidaK, YoshidaK, FujiwaraN, OnoK, EguchiT, KawaiH, GuoJ, WengY, HaozeY, UchibeK, IkegameM, SasakiA, NagatsukaH, OkamotoK, OkamuraH, OzakiK (2020) Outer membrane vesicles of Porphyromonas gingivalis attenuate insulin sensitivity by delivering gingipains to the liver. Biochim Biophys Acta Mol Basis Dis1866, 165731.
58.
DanaeiM, DehghankholdM, AtaeiS, Hasanzadeh DavaraniF, JavanmardR, DokhaniA, KhorasaniS, MozafariMR (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics18, 57.
HelmsHC, AbbottNJ, BurekM, CecchelliR, CouraudPO, DeliMA, FörsterC, GallaHJ, RomeroIA, ShustaEV, StebbinsMJ, VandenhauteE, WekslerB, BrodinB (2016) In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab36, 862–890.
61.
IaroshOA (1992) [Mathematical analysis of permeability of the blood-brain barrier in bacterial meningoencephalitis]. Zh Nevropatol Psikhiatr Im S S Korsakova92, 9233–9236.
62.
KanohY, OharaT, AkahoshiT (2011) Acute inflammatory biomarkers in cerebrospinal fluid as indicators of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitis. Clin Lab57, 37–46.
63.
BlufsteinA, BehmC, NguyenPQ, Rausch-FanX, AndrukhovO (2018) Human periodontal ligament cells exhibit no endotoxin tolerance upon stimulation with Porphyromonas gingivalis lipopolysaccharide. J Periodont Res53, 589–597.
64.
HirasawaM, Kurita-OchiaiT (2018) Porphyromonas gingivalis induces apoptosis and autophagy via ER stress in human umbilical vein endothelial cells. Mediators Inflamm2018, 1967506.
65.
WilhelmI, FazakasC, KrizbaiIA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp71, 113–128.
66.
HoffmannA, BrednoJ, WendlandM, DeruginN, OharaP, WintermarkM (2011) High and low molecular weight Fluorescein Isothiocyanate (FITC)-Dextrans to assess blood-brain barrier disruption: Technical considerations. Transl Stroke Res2, 106–111.
67.
FabryZ, FitzsimmonsKM, HerleinJA, MoningerTO, DobbsMB, HartMN (1993) Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes. J Neuroimmunol47, 23–34.
68.
BehmC, BlufsteinA, AbhariSY, KochC, GahnJ, SchäfferC, MoritzA, Rausch-FanX, AndrukhovO (2020) Response of human mesenchymal stromal cells from periodontal tissue to LPS depends on the purity but not on the LPS source. Mediators Inflamm2020, 8704896.
69.
OlsenI, Progulske-FoxA (2015) Invasion of Porphyromonas gingivalis strains into vascular cells and tissue. J Oral Microbiol7, 28788.
70.
CoatsSR, KantrongN, ToTT, JainS, GencoCA, McLeanJS, DarveauRP (2019) The distinct immune-stimulatory capacities of Porphyromonas gingivalis strains 381 and ATCC 33277 are determined by the fimB allele and gingipain activity. Infect Immun87, e00319.
71.
BergmannS, LawlerSE, QuY, FadzenCM, WolfeJM, ReganMS, PenteluteBL, AgarN, ChoCF (2018) Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics. Nat Protoc13, 2827–2843.
KalashD, VovkA, HuangH, AukhilI, WalletSM, ShaddoxLM (2015) Influence of periodontal therapy on systemic lipopolysaccharides in children with localized aggressive periodontitis. Pediatr Dent37, 35–40.
74.
WahaidiVY, KowolikMJ, EckertGJ, GalliDM (2011) Endotoxemia and the host systemic response during experimental gingivitis. J Clin Periodontol38, 412–417.
ZhaoY, JaberV, LukiwWJ (2017) Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): Detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol7, 318.
77.
Vargas-CaraveoA, SaydA, MausSR, CasoJR, MadrigalJLM, García-BuenoB, LezaJC (2017) Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport mechanism in physiological conditions. Sci Rep7, 13113.
78.
JaegerLB, DohguS, SultanaR, LynchJL, OwenJB, EricksonMA, ShahGN, PriceTO, Fleegal-DemottaMA, ButterfieldDA, BanksWA (2009) Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun23, 507–517.
79.
BryantCE, SpringDR, GangloffM, GayNJ (2010) The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol8, 8–14.
80.
MorrisMC, GilliamEA, LiL (2015) Innate immune programing by endotoxin and its pathological consequences. Front Immunol5, 680.
SandiegoCM, GallezotJD, PittmanB, NabulsiN, LimK, LinSF, MatuskeyD, LeeJY, O’ConnorKC, HuangY, CarsonRE, HannestadJ, CosgroveKP (2015) Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A112, 12468–12473.
83.
SkellyDT, HennessyE, DansereauMA, CunninghamC (2013) A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1β, TNF-α and IL-6 challenges in C57BL/6 mice. PLoS One8, e69123.
84.
EigenmannDE, XueG, KimKS, MosesAV, HamburgerM, OufirM (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS10, 33.
85.
BelardiB, Hamkins-IndikT, HarrisAR, KimJ, XuK, FletcherDA (2020) A weak link with actin organizes tight junctions to control epithelial permeability. Dev Cell54, 792–804.e7.
StamatovicSM, JohnsonAM, KeepRF, AndjelkovicAV (2016) Junctional proteins of the blood-brain barrier: New insights into function and dysfunction. Tissue Barriers4, e1154641.
